Management of Testosterone-Induced Leg Swelling

Patient Assessment and Monitoring

The American Urological Association recommends assessing for heart failure and evaluating hematocrit levels immediately in patients on testosterone therapy, as testosterone commonly causes erythrocytosis, which increases blood viscosity and can contribute to peripheral edema 1
The American Heart Association suggests checking cardiovascular risk factors, including fixed risks and modifiable risks, as testosterone may exacerbate underlying cardiovascular disease 2

The Endocrine Society recommends that if hematocrit exceeds 54%, intervention is mandatory, with options including dose reduction, temporary discontinuation, therapeutic phlebotomy, or blood donation 2, 1
The American College of Cardiology suggests that for symptomatic fluid retention without elevated hematocrit, reducing testosterone dose or temporarily discontinuing therapy until swelling resolves is recommended 1

The American Urological Association notes that injectable testosterone is associated with the greatest treatment-induced increases in hemoglobin/hematocrit and erythrocytosis rates of 43.8% 2, 1
The Endocrine Society recommends considering a formulation switch, as transdermal preparations are preferable for patients with fluid retention, with gels at 5 mg/day causing erythrocytosis in only 2.8% of patients 1

The American College of Cardiology recommends reassessing patients at 1-2 months after dose reduction or formulation change to evaluate resolution of edema, and measuring hematocrit/hemoglobin at this visit to ensure normalization if previously elevated 2
The Endocrine Society suggests monitoring patients every 3-6 months for the first year, then annually if stable, and targeting mid-range testosterone levels (350-600 ng/dL) to minimize adverse effects including fluid retention 4

The American Heart Association recommends considering therapeutic phlebotomy or blood donation to reduce blood viscosity if erythrocytosis is contributing to symptoms 1
The American Urological Association suggests reassessing indication for therapy, confirming the patient has documented testosterone deficiency with levels <230 ng/dL or symptomatic levels between 231-346 ng/dL, as therapy should not continue in eugonadal men 4